RxDoctor Payments Data

Jack Khouri, MD

Medical Oncology · Cleveland, OHNPI 1851739668

Payments from drug & device makers

$141,870in general payments, 2019–2025

Across 66 payments — averaging $2149.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$81K
  • GSK$30K
  • Gilead$9K
  • Johnson & Johnson$7K
  • E.r. Squibb & Sons, L.L.C.$6K
  • Legend Biotech USA Inc.$6K
  • plus $4K from 10 others

What the payments were for

  • Consulting fees$28,37373%
  • Travel & lodging$1,8615%
  • Food & beverage$2,5747%
  • Education$6,20916%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,870 in reported general payments places this provider in the 60th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$57,891
Medicare patients
163
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide119$1,422,002
PomalystPomalidomide49$1,079,163
RevlimidLenalidomide60$940,192
VenclextaVenetoclax13$292,451
NinlaroIxazomib Citrate11$154,302
ZarxioFilgrastim-Sndz12$40,234
EliquisApixaban49$34,977
XareltoRivaroxaban45$31,996
Acyclovir142$2,769
Ondansetron Hcl22$473
Pantoprazole Sodium11$353
Gabapentin22$313
Potassium Chloride22$269
Dexamethasone21$222
Klor-Con M20Potassium Chloride15$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$6,098$1,079,16349 claims
AbbVieVenclexta$80$292,45113 claims
PfizerEliquis$120$34,97749 claims
Johnson & JohnsonXarelto$6,929$31,99645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 157 medical oncology providers in Ohio.

Other medical oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →